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Abstract
Background—The melanocortin (MC) system is composed of peptides that are cleaved from the
polypeptide precursor proopiomelanocortin. A growing body of literature suggests that the MC
system modulates neurobiological responses to drugs of abuse. Because ethanol has direct effects on
central proopiomelanocortin activity, it is possible that MC neuropeptides participate in the control
of voluntary ethanol consumption. Here we assessed the possibility that MC receptor (MCR) agonists
modulate ethanol intake via the MC3 receptor (MC3R) and/or the MC4 receptor (MC4R) and whether
the MCR antagonist AgRP-(83-132) controls ethanol consumption.
Methods—Mc3r-deficient (Mc3r−/−) and wild-type (Mc3r+/+) littermate mice were given
intraperitoneal (10 mg/kg) and intracerebroventricular (1.0 μg ICV) doses of melanotan II (MTII),
a nonselective MCR agonist. To assess the role of MC4R, C57BL/6J mice were given an ICV infusion
of the highly selective MC4R agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-NH2 (1.0
or 3.0 μg). Finally, naïve C57BL/6J mice were given an ICV infusion of AgRP-(83-132) (0.05 and
1.0 μg).
Results—MTII was similarly effective at reducing ethanol drinking in Mc3r-deficient (Mc3r−/−)
and wild-type (Mc3r+/+) littermate mice. Furthermore, ICV infusion of the MC4R agonist
significantly reduced ethanol drinking, whereas ICV infusion of AgRP-(83-132) significantly
increased ethanol drinking in C57BL/6J mice. Neither MTII nor AgRP-(83-132) altered blood
ethanol levels at doses that modulated ethanol drinking.
Conclusions—The present results suggest that MC4R, and not MC3R, modulates MCR agonist–
induced reduction of ethanol consumption and that ethanol intake is increased by the antagonistic
actions of AgRP-(83-132). These findings strengthen the argument that MCR signaling controls
ethanol consumption and that compounds directed at MCR may represent promising targets for
treating alcohol abuse disorders in addition to obesity.
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THE MELANOCORTIN (MC) system is composed of peptides that are cleaved from the
polypeptide precursor proopiomelanocortin (POMC). Central MC peptides are produced by
neurons within the hypothalamic arcuate nucleus and the medulla (Dores et al., 1986;
Jacobowitz and O’Donohue, 1978; O’Donohue and Dorsa, 1982). These peptides include
adrenocorticotropic hormone, α-melanocyte–stimulating hormone (α-MSH), β-MSH, and γ-
MSH (Hadley and Haskell-Luevano, 1999). Genetic and pharmacological evidence reveals
that MC receptor (MCR) signaling is involved in grooming behavior (Gispen et al., 1975),
antipyretic (Murphy et al., 1983) and anti-inflammatory (Macaluso et al., 1994) responses,
learning (Zhao et al., 1995), reproductive function (Schioth and Watanobe, 2002), and
regulation of appetite and energy homeostasis (Chen et al., 2000; Fan et al., 1997; Huszar et
al., 1997; Marsh et al., 1999; Schwartz and Wisse, 2000).
There are several observations that suggest that the MC system is a prime candidate for
regulating drug-seeking behavior. MCRs are expressed in brain regions thought to mediate
drug self-administration, including the nucleus accumbens (NAcc), the hypothalamus, and the
ventral tegmental area (VTA) (Alvaro et al., 1996; Griffon et al., 1994; Mountjoy et al.,
1994; Roselli-Rehfuss et al., 1993). Interestingly, α-MSH administered into the VTA increases
dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the NAcc (Lindblom et al.,
2001), and chronic intracerebroventricular (ICV) infusion of the nonselective MCR agonist
melanotan II (MTII) to rats increases dopamine D1 receptor binding in the NAcc and dopamine
D2 receptor binding in the VTA, suggesting that MTII alters dopamine signaling in these
regions (Lindblom et al., 2002a). Chronic treatment of a high dose of morphine decreases MC4
receptor (MC4R) mRNA expression in the NAcc, the periaqueductal gray, and neostriatum
(Alvaro et al., 1996), brain regions that modulate drug reward, opiate tolerance, and
psychomotor stimulation, respectively (Kalivas and Stewart, 1991; Koob and Bloom, 1988;
Wise and Bozarth, 1987). On the other hand, chronic treatment with low doses of morphine or
cocaine increases MC4R mRNA in the striatum and hippocampus (Alvaro et al., 2003).
Consistent with a role in drug self-administration, central infusion of an MCR agonist decreases
the acquisition of heroin self-administration in rats (van Ree et al., 1981).
Ethanol has direct effects on central POMC and α-MSH activity (Angelogianni and
Gianoulakis, 1993; Rainero et al., 1990). It is therefore possible that MC neuropeptides
modulate neurobiological responses to ethanol and participate in the control of voluntary
ethanol consumption. Several observations are consistent with this hypothesis. First, α-MSH
is expressed in brain regions involved with neurobiological responses to ethanol, including the
striatum, NAcc, VTA, amygdala, hippocampus, and hypothalamus (Bloch et al., 1979; Dube
et al., 1978; Jacobowitz and O’Donohue, 1978; O’Donohue and Jacobowitz, 1980; O’Donohue
et al., 1979; Yamazoe et al., 1984). Second, rats selectively bred for high ethanol drinking (AA
[Alko, alcohol]) have low levels of MC3R in the shell of the NAcc but have high levels of
MC3R and MC4R in various regions of the hypothalamus, when compared with low–ethanol-
drinking rats (Lindblom et al., 2002b). Third, central infusion of MTII significantly reduces
voluntary ethanol drinking in AA rats with an established history of ethanol intake (Ploj et al.,
2002). Recently, MTII-induced reduction of ethanol consumption was shown to be receptor
mediated and not associated with alterations of ethanol metabolism in C57BL/6 mice (Navarro
et al., 2003).
One objective of the present report was to study the role of selected MCRs in the modulation
of MCR agonist–induced reduction of ethanol intake. In rodents, MC peptides act through five
receptors (MC1R–MC5R) (Hadley and Haskell-Luevano, 1999). MC3R and MC4R are
expressed at high levels in the brain (Alvaro et al., 1997), whereas MC1R and MC5R are
detected at low levels and in only limited brain regions (Adan and Gispen, 1997; Barrett et al.,
1994; Xia et al., 1995). MTII binds, with varying affinity, to all centrally expressed MCRs
(Haskell-Luevano et al., 1997; Schioth et al., 1997). Thus, it is unclear which MCRs are
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important for modulating MTII-induced reductions of ethanol consumption (Navarro et al.,
2003; Ploj et al., 2002). To assess the contribution of MC3R, we examined MTII-induced
alteration of ethanol drinking in Mc3r–knock-out (Mc3r−/−) and wild-type (Mc3r+/+) mice. To
assess the role of MC4R, we studied ethanol intake by C57BL/6J mice after central infusion
of the highly selective MC4R agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-
NH2. A second objective was to determine whether central administration of AgRP-(83-132)
would increase ethanol consumption by mice. In vivo, AgRP-(83-132) is a potent and
nonselective MCR antagonist (Quillan et al., 1998). Such results would strengthen the
argument that MCR signaling plays an important role in the modulation of ethanol self-
administration. Because MCR agonists reduce and MCR antagonists increase feeding (Hagan
et al., 2000; Hohmann et al., 2000; Hollopeter et al., 1998; Marsh et al., 1999; Thiele et al.,
1998), food intake was concurrently assessed in most studies described in the present report.
METHODS
Animals
The generation of Mc3r−/− mice has been described (Chen et al., 2000). Mc3r−/− mice are born
at the expected frequency and are viable and fertile. Furthermore, gross anatomical and
histological assessment of these mice has revealed no abnormalities of brain or other organs
(Chen et al., 2000). For the first 6 months of development, Mc3r−/− mice show normal body
weight, food intake, and activity. Beginning at approximately 25 weeks of age, Mc3r−/− mice
maintained on normal chow begin to show increased body weight associated with increased
fat mass and reduced lean mass. Increased fat mass in Mc3r−/− mice is associated with increased
blood levels of leptin and insulin. Despite increased fat mass, Mc3r−/− mice show hypophagia
(Chen et al., 2000). Therefore, to avoid possible confounding associated with late-onset
developmental changes, the studies in this report used 8- to 12-week-old mice at study onset
to allow sufficient time for testing before changes occurred. Mc3r−/− mice were originally
maintained on a C57BL/6J × 129/SvJ genetic background (Chen et al., 2000) but have now
been backcrossed to a C57BL/6J genetic background seven times. Nonlittermate heterozygous
(Mc3r±) mice were bred, resulting in N7 Mc3r−/− and Mc3r+/+ littermate mice. The studies
described included male and female Mc3r−/− and littermate Mc3r+/+mice. Because sex was not
found to interact with the experimental manipulations in these studies, data for male and female
mice were collapsed for statistical analyses. Some studies used male C57BL/6J mice purchased
from Jackson Laboratory (Bar Harbor, ME). Mice were individually housed in polypropylene
cages with wood-chip bedding and had ad libitum access to standard rodent chow (Teklad,
Madison, WI) and water throughout the experiments, except where noted. The colony room
was maintained at approximately 22°C with a 12-hr/12-hr light/dark cycle. All procedures used
in the present research were in compliance with National Institutes of Health guidelines, and
the protocols were approved by the University of North Carolina Animal Care and Use
Committee.
Cannulation Surgery and Infusion Procedures
For studies involving ICV infusions, mice were anesthetized with a cocktail of ketamine (117
mg/kg) and xylazine (7.92 mg/kg) and surgically implanted with a 26-gauge cannula (Plastic
One, Roanoak, VA) aimed at the left lateral ventricle, with the following stereotaxic
coordinates: 0.2 mm posterior to the bregma, 1.0 mm lateral to the midline, and 2.3 mm ventral
to the skull surface. Mice were allowed to recover for approximately 2 weeks before
experimental procedures were initiated. After experimental procedures, cannula placement was
verified histologically. The ICV infusions were given in a 1.0 μl volume over a 1-min period
with a 5.0 μl Hamilton syringe, infused manually or with a Harvard Apparatus PHD 2000
microinfusion pump.
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Ethanol Consumption and Food Intake After Peripheral Injection of MTII to Mc3r−/− and
Mc3r+/+ Mice
Mc3r−/− and Mc3r+/+ mice were given 24-hr access to two bottles, one containing plain water
and the other containing ethanol in water. To habituate mice to drinking ethanol, the
concentration (v/v) was increased every 8 days; mice received 3, 6, 10, and finally 20% ethanol.
The positions of the bottles were changed every 2 days to control for position preferences.
These data were analyzed with a two-way, 2 × 4 (genotype × concentration) repeated-measures
ANOVA. Mice were then distributed to two groups per genotype based on average voluntary
ethanol consumption (g/kg/day) of 20% ethanol. Two hours before the beginning of the dark
phase of the light cycle, mice were weighed, and ethanol, water, and food were removed from
the cages. One hour later, mice were given an intraperitoneal (ip) injection of either 10 mg/kg
MTII (2.0 mg/ml in isotonic saline; Bachem, Torrance, CA) (Mc3r−/− mice, n = 11; Mc3r+/+
mice, n = 12) or an equal volume of isotonic saline (Mc3r−/− mice, n = 11; Mc3r+/+ mice, n =
13). When administered peripherally, this dose of MTII was found to decrease food intake by
mice without producing aversive side effects (Chen et al., 2000). Mice were immediately
returned to their cages. Just before the dark cycle, ethanol, water, and food were returned to
the cages. Intake measures were recorded every 2 hr for up to 8 hr into the dark cycle and again
at 24 hr after treatment. Two-way, 2 × 2 (genotype × drug) ANOVAs were used to assess
consumption data. All data in this report are presented as mean ± SEM, and ethanol and food
intake data are presented to the longest time point that the drug [MTII, MC4RA, or AgRP-
(83-132)] significantly altered consumption. In all cases, significance was accepted at p < 0.05
(two tailed).
Ethanol Consumption and Food Intake After Central Infusion of MTII to Mc3r−/− and Mc3r+/+
Mice
After recovery from surgery, mice were habituated to drinking 20% ethanol similar to the
procedure already described and were distributed to groups based on average ethanol
consumption (g/kg/day).
Mice were weighed, and ethanol, water, and food were removed from their cages 2 hr before
the beginning of the dark cycle. One hour before the beginning of the dark cycle, mice were
given an ICV infusion of either 1.0 μg MTII (Mc3r−/− mice, n = 9; Mc3r+/+ mice, n = 8)
dissolved in artificial cerebrospinal fluid (aCSF; Harvard Apparatus, Holliston, MA) or an
equal volume of aCSF (Mc3r−/− mice, n = 9; Mc3r+/+ mice, n = 9) and were returned to their
cages. The 1.0 μg dose of MTII was chosen because a similar dose (1.0 nmol, where 1.0 nmol
= 1.02 μg) was found to reduce ethanol drinking by AA rats (Ploj et al., 2002) and C57BL/6
mice (Navarro et al., 2003). The 20% ethanol solution, water, and food were returned
immediately before the dark cycle. Two-way, 2 × 2 (genotype × drug) ANOVAs were used to
assess consumption data. To determine whether the MTII-induced reduction of ethanol
drinking depended on the presence of food, an additional study was performed in which
C57BL/6J mice were given an ICV infusion of aCSF (n = 10) or 1.0 μg MTII (n = 9) in a similar
procedure as describe previously, except that food was not returned to the cage with ethanol
and water immediately before the dark cycle (food was returned 10 hr later). Data from this
study were analyzed with a one-way (drug) ANOVA.
Ethanol Consumption and Food Intake After Central Infusion of a Selective MC4R Agonist
C57BL/6J mice were implanted with an ICV cannula and acclimated to the two-bottle
consumption procedure as described before. On the test day, mice were weighed, and ethanol,
water, and food were removed from their cages 2 hr before the beginning of the dark cycle.
One hour before the beginning of the dark cycle, mice were given ICV infusions of either 1.0
(n = 7) or 3.0 (n = 8) μg of the MC4R-selective agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-
Arg-Trp-Glu)-NH2 (Phoenix Pharmaceuticals, Inc., Belmont, CA) dissolved in aCSF or an
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equal volume of aCSF (n = 10). This compound is a potent agonist at the human MC4R with
90-fold selectivity over human MC3R and approximately 3400-fold selectivity over MC5R,
as assessed by adenosine 3’:5’-cyclic monophosphate induction (Bednarek et al., 2001). We
included a larger dose of the selective MC4R agonist than MTII (3.0 vs. 1.0 μg) because this
compound has weaker binding potency (~16%) and adenosine 3’:5’-cyclic monophosphate
induction (~80%) at MC4R relative to MTII (Bednarek et al., 2001). The 20% ethanol solution,
water, and food were returned immediately before the dark cycle. One-way (drug) ANOVAs
were used to assess consumption measures after ICV infusion of the MC4R agonist or aCSF.
Ethanol Consumption and Food Intake After Central Infusion of AgRP-(83-132)
C57BL/6J mice were implanted with an ICV cannula and acclimated to the two-bottle
consumption procedures as described before. Mice were weighed, and ethanol, water, and food
were removed from their cages 2 hr before the beginning of the dark cycle. One hour before
the beginning of the dark cycle, mice were given ICV infusions of 0.05 (n = 6) or 0.1 (n = 11)
μg of AgRP-(83-132) (Phoenix Pharmaceuticals, Inc., Belmont, CA) or an equal volume of
aCSF (n = 9). The 20% ethanol solution, water, and food were returned immediately before
the dark cycle. One-way (drug) ANOVAs were used to assess consumption data.
Blood Ethanol Level Assessment
To determine whether peripherally administered MTII influenced blood ethanol levels,
C57BL/6J mice were divided into two groups based on body weight and given an ip injection
of either 10 mg/kg MTII (n = 19) or an equal volume of saline (n = 18). Ten minutes later, all
mice were given ip injections of ethanol (3.0 g/kg; 20% [w/v] in isotonic saline) and
immediately returned to their homecages. Two hours after injection, half the mice from each
group were rapidly decapitated for blood collection. The remaining mice were decapitated 4
hr after ethanol injection. Blood ethanol levels were determined by spectrophotometric
methods (Sigma Diagnostics, Enzymatic Determination of Ethanol Test, St. Louis, MO) and
calculated as mg/dl. A two-way 2 × 2 (drug × time interval) ANOVA was used to analyze the
data.
To determine whether ICV infusion of AgRP-(83-132) influenced blood ethanol levels, naïve
C57BL/6J mice were divided into two groups based on body weight and given ICV infusions
of either 0.05 μg AgRP-(83-132) (n = 8) or an equal volume of aCSF (n = 7) according to the
procedures described before. Approximately 10 min later, all mice were given an ip injection
of ethanol (4.0 g/kg; 20% [w/v] mixed in isotonic saline) and immediately returned to their
homecages. Two and 4 hr after injection, mice tails were cleaned, and sterile single-blade razors
were used to make small tail-tip nicks for blood collection. Blood ethanol samples were
analyzed with gas chromatographic methods described elsewhere (Knapp et al., 1993; Navarro
et al., 2003). A two-way, 2 × 2 (genotype × time interval) repeated-measures ANOVA was
used to assess blood ethanol levels using gas chromatography.
RESULTS
Peripheral Injection of MTII Reduces Ethanol Drinking and Food Intake in Mc3r−/− and
Mc3r+/+ Mice
Relative to wild-type mice, Mc3r−/− mice did not show altered ethanol preference during
habituation to ethanol consumption (Fig. 1A). ANOVA performed on the ethanol-preference
ratio data showed a significant effect of ethanol concentration [F(3,138) = 131.49; p < 0.001];
as the concentration of ethanol increased from 10 to 20%, the ethanol-preference ratio
decreased below 0.5, a finding indicating that the mice preferred water to the ethanol solution.
Ethanol-preference ratios ranging from approximately 0.2 to 0.8 have been reported with mice
given access to a 20% ethanol solution (Thiele et al., 2000;Wang et al., 2003). Intraperitoneal
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injection of MTII (10.0 mg/kg) significantly reduced ethanol intake (Fig. 1B) and the ethanol-
preference ratio (Fig. 1C) for up to 24 hr, regardless of genotype. ANOVA performed on
consumption data (g/kg) showed a significant effect of the drug [F(1,43) = 5.08; p = 0.029].
Neither the genotype nor interaction effects reached significance. Similarly, ANOVA
performed on preference ratio data showed a significant drug effect [F(1,43) = 7.19; p = 0.01],
but the genotype and interaction effects were not significant. While causing 24-hr reductions
of ethanol drinking, ip injection of MTII did not alter 24-hr water drinking by Mc3r−/− (204.5
± 16.38 ml/kg) or Mc3r+/+ (215.31 ± 15.69 ml/kg) mice relative to Mc3r−/− (169.41 ± 16.3 ml/
kg) and Mc3r+/+ (200.12 ± 15.07 ml/kg) mice injected with saline. Finally, ip administration
of MTII caused significant reductions of food intake only up to the 4-hr measure in both
Mc3r−/− (44.29 ± 4.02 g/kg) and Mc3r+/+ (41.02 ± 3.85 g/kg) mice relative to Mc3r−/− (67.13
± 4.03 g/kg) and Mc3r+/+ (71.12 ± 3.70 g/kg) mice injected with saline. ANOVA performed
on 4-hr food intake data showed a significant effect of drug [F(1,43) = 45.88; p < 0.001], but
once again, the genotype and interaction effects were not significant.
Peripheral Injection of MTII Does Not Alter Blood Ethanol Levels
Relative to saline, ip injection of MTII (10.0 mg/kg) did not significantly alter blood ethanol
levels 2 hr after a 3.0 g ethanol/kg dose (MTII, 232.09 ± 7.44 mg/dl; saline, 233.60 ± 7.43 mg/
dl). Four hours after ethanol injection, plasma ethanol levels were lower, but again, there was
no significant effect of MTII treatment (MTII, 89.62 ± 7.83 mg/dl; saline, 74.25 ± 8.31 mg/
dl). ANOVA performed on plasma ethanol data showed a significant effect of time [F(1,33)
= 377.85; p < 0.001], which reflected the reduced levels of ethanol in plasma from 2 to 4 hr
after injection. However, neither the effect of MTII injection nor the interaction effect was
significant.
Central Infusion of MTII Reduces Ethanol Drinking and Food Intake in Mc3r−/− and Mc3r+/+
Mice
Relative to mice given ICV infusions of aCSF, central infusion of a 1.0 μg dose of MTII
significantly reduced ethanol intake (Fig. 2A) and ethanol-preference ratio (Fig. 2B) for up to
24 hr after infusion in both Mc3r−/− and Mc3r+/+ mice. ANOVA performed on consumption
data (g/kg) revealed a significant effect of drug [F(1,31) = 9.98; p = 0.004]; however, neither
the genotype nor the interaction effects reached levels of significance. ANOVA performed on
24-hr preference ratio data also showed a significant drug effect [F(1,31) = 19.86; p < 0.001]
and no significant genotype or interaction effects. Interestingly, ethanol consumption levels
were higher in the ICV study (Fig. 2A) than in the study involving ip injection of MTII (Fig.
1B). Ethanol consumption levels by C57BL/6 mice are reported to be approximately 20 g/kg/
day in young mice (6–10 weeks) and decrease to approximately 10 to 15 g/kg/day as mice age
(26–28 weeks) (Wang et al., 2003). Because mice from the ip injection study were older (~17
weeks) than mice from the ICV study (~10 weeks), difference in ethanol consumption between
studies may be age dependent.
Infusion (ICV) of MTII was not associated with altered drinking from the water bottle at the
24-hr measure by Mc3r−/− (158.64 ± 16.29 ml/kg) and Mc3r+/+ (159.59 ± 22.68 ml/kg) mice
relative to Mc3r−/− (115.32 ± 10.96 ml/kg) and Mc3r+/+ (126.25 ± 26.27 ml/kg) treated with
aCSF, although there was a trend for increased water drinking by MTII-treated mice (p = 0.06).
As with the ip injection study, ICV infusion of MTII caused significant reductions of food
intake only up to 4 hr in both Mc3r−/− (20.21 ± 4.29 g/kg) and Mc3r+/+ (36.64 ± 7.28 g/kg)
mice relative to Mc3r−/− (58.80 ± 4.04 g/kg) and Mc3r+/+ (52.12 ± 5.87 g/kg) mice infused
with aCSF. ANOVA performed on 4-hr food intake data revealed a significant drug effect [F
(1,31) = 25.02; p < 0.001]. Finally, ICV infusion of a 1.0 μg dose of MTII significantly reduced
ethanol intake (1.19 ± 0.31 g/kg/10 hr) relative to treatment with aCSF (5.77 ± 1.09 g/kg/10
hr) in C57BL/6J mice presented with ethanol and water but no food [F(1,17) = 14.71; p =
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0.001]. Thus, the presence of food is not necessary for MTII-induced reduction of ethanol
drinking.
Central Infusion of a Selective MC4R Agonist Reduces Ethanol Drinking and Food Intake
Infusion (ICV) of the MC4R agonist significantly and dose-dependently reduced ethanol
consumption (Fig. 3A) and food intake (Fig. 3B) for up to 2 hr after infusion when compared
with aCSF-treated mice. ANOVAs performed on ethanol consumption data [F(1,22) = 4.75;
p = 0.001] and food intake data [F(1,22) = 10.31; p = 0.001] were both significant, and post
hoc tests confirmed that the 1.0 and 3.0 μg doses of the MC4R agonist reduced ethanol and
food ingestion. Relative to aCSF infusion (24.88 ± 5.51 ml/kg), neither the 1.0 (11.13 ± 5.55
ml/kg) nor the 3.0 (8.45 ± 4.40 ml/kg) μg dose of the MC4R agonist significantly reduced 2-
hr water drinking, although there was a trend (p = 0.07). Although reductions of 2-hr water
drinking may suggest possible aversive side effects, it is typical to find that MCR agonists
concurrently reduce short-term feeding and water drinking, whereas MCR antagonists increase
short-term food intake and water consumption (Fan et al., 1997;Grill et al., 1998). This pattern
of results suggests the possibility that alterations of water drinking caused by MCR compounds
may be the direct result of changes in food intake, rather than a marker of aversion.
Central Infusion of AgRP-(83-132) Increases Ethanol Drinking
As shown in Fig. 4A, ICV infusion of the 0.05 μg dose of AgRP-(83-132) significantly
increased ethanol consumption for up to 8 hr when compared with mice treated with aCSF [F
(2,23) = 4.63; p = 0.02]. Post hoc tests confirmed this conclusion. However, neither the 0.05
nor the 0.1 μg dose of AgRP-(83-132) altered food intake at the 8- (Fig. 4B) or 24-hr measure.
A higher, 5.0 μg dose of AgRP-(83-132) was also found not to alter 8-hr food intake or ethanol
drinking by C57BL/6J mice (Navarro et al., 2003). Further assessment of these data revealed
that the 5.0 μg dose of AgRP-(83-132) caused a significant increase of food intake at the 24-
hr measure (165.24 ± 20.36 g/kg) relative to aCSF (105.84 ± 13.56 g/kg) [F(1,26) = 5.89; p =
0.02] without influencing ethanol consumption.
Central Infusion AgRP-(83-132) Does Not Alter Blood Ethanol Levels
Data from blood ethanol levels after ICV infusion of AgRP-(83-132) are presented in Fig.
4C. Blood ethanol levels 2 hr after ip injection of a 4.0 g ethanol/kg dose did not differ
significantly between mice pretreated with 0.05 μg AgRP-(83-132) versus aCSF. Four hours
after ethanol injection, blood ethanol levels were lower, but again, there was no significant
effect of ICV treatment. A two-way, 2 × 2 (ICV treatment × hr) repeated-measures ANOVA
performed on these data revealed a significant effect of hr [F(1,13) = 28.10; p < 0.001], which
reflected the reduced levels of blood ethanol from 2 to 4 hr after injection. However, neither
the effect of ICV treatment nor the interaction effect was significant.
DISCUSSION
The present studies reveal four important points regarding the role of MCR signaling in ethanol
consumption. First, a highly selective MC4R agonist reduces ethanol consumption by C57Bl/
6J mice, suggesting that MC4R is a likely receptor for mediating MCR agonist–induced
reduction of ethanol consumption. Second, Mc3r−/− mice respond normally to MTII,
suggesting that MC3R is not a likely receptor for mediating MCR agonist–induced reduction
of ethanol drinking. Third, ethanol intake is increased by the antagonistic actions of AgRP-
(83-132) in C57BL/6J mice. Fourth, compounds that target MCR modulate ethanol intake
without altering ethanol metabolism.
The MC4R agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-NH2 significantly
reduces ethanol drinking. This compound is a highly selective agonist for MC4R, with 90-fold
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selectivity over MC3R and a > 3400-fold selectivity over MC5R (Bednarek et al., 2001). Thus,
we conclude that activation of MC4R modulates ethanol consumption in mice. However, the
present results do not support a role for MC3R. When compared with littermate control mice,
Mc3r−/− mice exhibit a normal preference of solutions containing various concentrations of
ethanol. However, the Mc3r−/− mice were maintained on a high–ethanol-drinking C57Bl/6J
genetic background (Belknap et al., 1993), which may have masked genotype differences in
ethanol consumption. Additional studies with Mc3r−/− mice maintained on more moderate
ethanol-consuming genetic backgrounds will be necessary to more firmly establish the role of
MC3R in voluntary ethanol consumption. Consistent with previous research (Navarro et al.,
2003; Ploj et al., 2002), MTII administered via ICV infusion (1.0 μg) or by ip injection (10
mg/kg) causes reductions of voluntary ethanol drinking for up to 24 hr, and these routes of
administration are similarly effective in Mc3r−/− and Mc3r+/+ mice. These findings indicate
that MTII’s effect on ethanol drinking does not require MC3R signaling. Because the MC4R
agonist reduces ethanol drinking by mice and MTII-induced reduction of ethanol drinking is
receptor mediated (Navarro et al., 2003) and given the limited expression of MC1R and MC5R
in the brain (Adan and Gispen, 1997; Barrett et al., 1994; Xia et al., 1995), MTII likely reduces
ethanol drinking by acting at MC4R.
Reductions of ethanol drinking caused by MTII and the MC4R agonist cannot be explained by
general decreases in fluid consumption. Neither administration of MTII (ip or ICV) nor ICV
infusion of the MC4R agonist significantly altered water drinking. Furthermore, MTII-induced
reduction of ethanol drinking is not likely related to ethanol metabolism, as we have previously
shown that ICV infusion of a 1.0-μg dose of MTII does not alter blood ethanol levels in C57BL/
6 mice (Navarro et al., 2003), and we show here that ip injection of MTII does not alter plasma
ethanol levels. Central and peripheral routes of administration of MTII promote conditioned
taste aversion to novel flavors in rats (Benoit et al., 2003; Thiele et al., 1998); thus, MTII-
induced reduction of feeding and ethanol drinking could be mediated, at least in part, by
aversive consequences of MTII. Although we cannot completely rule out aversive effects here,
as noted earlier, MTII and the MC4R agonist do not reduce water drinking by mice. We would
predict that mice should show general decreases of consummatory behavior (including water
drinking) if they experience aversive effects such as visceral illness or malaise. Furthermore,
increased ethanol drinking caused by AgRP-(83-132) administration is unlikely to be related
to any possible aversive consequences.
AgRP-(83-132) has been shown to increase food intake after central infusion (Hagan et al.,
2000; Small et al., 2001). Here we show that ICV infusion of a 0.05-μg dose of AgRP-(83-132)
increases ethanol drinking by C57BL/6J mice without modifying food intake. Because a 0.05-
μg dose of AgRP-(83-132) does not alter blood ethanol levels, AgRP-(83-132)–induced
increases of ethanol drinking are not caused by increased ethanol metabolism. Interestingly, a
recent report showed that an MC4R-selective antagonist (HS014) has no effect on ethanol
drinking by rats selectively bred for ethanol preference (Ploj et al., 2002). However, only one
dose of HS014 was tested in rats (Ploj et al., 2002), and other doses may be found to increase
ethanol drinking. It is also possible that AgRP-(83-132) modulates ethanol drinking by acting
at receptors other than the MC4R.
We propose two possible mechanisms by which MCR signaling modulates ethanol intake. The
MC system has been shown to modulate ingestive behavior (Fan et al., 1997; Hohmann et al.,
2000; Hollopeter et al., 1998; Marsh et al., 1999; Pierroz et al., 2002), and we show here that
MCR agonists and antagonist modulate food intake. Thus, MCR agonists and antagonists may
regulate feeding and ethanol consumption via the same or similar pathways. In fact, we believe
that this possibility should not come as a surprise in light of recent electrophysiological
evidence demonstrating that both drugs of abuse and “natural” reinforcers (food and water)
produce similar cell firing in the NAcc (Carelli et al., 2000; Hollander et al., 2002; Roop et al.,
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2002). Furthermore, there are examples of overlapping control of feeding and ethanol intake
by other neurochemical systems (Thiele et al., 2003; Thiele et al., 2004). It has been known
for some time that the peptide cholecystokinin reduces food intake and ethanol consumption
in a dose-dependent fashion (Avery and Livosky, 1986; DiBattista et al., 2003; Kulkosky and
Chavez, 1984; Kulkosky et al., 1991; Kulkosky and Glazner, 1988; Le Sauter et al., 1988), and
recent evidence shows that the orexigenic neuropeptide galanin (Kyrkouli et al., 1990; Tempel
et al., 1988) controls ethanol consumption (Leibowitz et al., 2003; Lewis et al., 2004). A
growing body of literature also shows that the central cannabinoid system modulates ethanol
self-administration and feeding (Colombo et al., 1998; Freedland et al., 2003; Poncelet et al.,
2003; Wang et al., 2003). Interestingly, it has been proposed that cannabinoid-1 receptor
antagonists may be useful therapeutic agents for treating obesity (Cota et al., 2003) and
alcoholism (Racz et al., 2003). Similarly, MCR agonists may be useful for treating alcoholism,
in addition to obesity. This being said, ICV infusion of a 0.05-μg dose of AgRP-(83-132)
increases ethanol drinking by C57BL/6J mice without modifying food intake. On the other
hand, the 5.0-μg dose of AgRP-(83-132) increases food, but not ethanol, consumption.
Furthermore, MTII reduced feeding for 4 hr but reduced ethanol drinking for up to 24 hr. Thus,
MCR signaling may modulate ethanol drinking and food intake through different central
pathways. Regardless, an important issue requiring resolution is whether MCR signaling
controls ethanol drinking through a mechanism involving the regulation of calories or by a
mechanism that modulates the pharmacodynamic effects of ethanol (e.g., the reinforcing
properties of ethanol as discussed next).
A second possibility is that compounds targeting MCRs modulate ethanol consumption by
acting on pathways involved with drug reward. MCR signaling has been implicated in opioid
tolerance and dependence (Contreras and Takemori, 1984; Szekely et al., 1979) and
amphetamine reward (Cabeza de Vaca et al., 2002), and MCRs are expressed in brain regions
that modulate the reinforcing properties of drugs of abuse and ‘natural’ reinforcers (e.g., food
and water), including the NAcc, the VTA, and the hypothalamus (Hadley and Haskell-
Luevano, 1999; Lindblom et al., 2002b). It is tempting to speculate that MCR agonists reduce
and AgRP-(83-132) increases ethanol consumption by acting on MCRs within the VTA–NAcc
circuit, perhaps by modulating the reinforcing properties associated with ethanol. Ploj et al.
(2002) proposed a mechanism that involves an interaction between endogenous opioids and
melanocortins. In addition to reducing ethanol drinking, central infusion of MTII prevents
ethanol-induced changes in opioid peptide levels in the VTA and the substantia nigra of AA
rats (Ploj et al., 2002). Thus, MCR signaling may regulate ethanol drinking by modulating
endogenous opioid activity within mesolimbic dopamine pathways (Ploj et al., 2002).
In conclusion, we extend recent findings (Lindblom et al., 2002b; Navarro et al., 2003; Ploj et
al., 2002) by showing that a highly selective MC4R agonist reduces ethanol drinking and
feeding, that MTII-induced reductions of ethanol drinking and food intake do not involve
MC3R, and that ethanol consumption is increased by antagonizing MCR signaling. These
findings strengthen the argument that modulation of MCR signaling controls ethanol
consumption. Important future research will determine whether MCR signaling controls
ethanol drinking through a mechanism involving the regulation of calories or by a mechanism
that modulates the pharmacodynamic effects of ethanol and whether ethanol administration
modulates central MC peptide, MCR, and/or agonti-related protein (AgRP) activity and
expression.
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Consumption of solutions containing ethanol by mice lacking Mc3r (Mc3r−/−) and by littermate
wild-type (Mc3r+/+) mice maintained on an inbred C57BL/6J genetic background. (A) Ethanol-
preference ratios (volume of ethanol consumed/total volume of fluid consumed) as a measure
of relative ethanol preference. (B) Consumption (g/kg/24 hr) of 20% ethanol solution after ip
injection of MTII (10 mg/kg) or an equal volume of saline. (C) 20% ethanol–preference ratio
(24 hr) after ip injection of MTII or saline. All values are means ± SEM. ANOVAs indicated
no significant differences between Mc3r−/− and Mc3r+/+ mice in ethanol preference (A). MTII
caused significant and similar reductions of ethanol drinking in both Mc3r−/− and Mc3r+/+ mice
(B and C).
*p < 0.05 relative to saline injection.
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Consumption of 20% ethanol expressed as g/kg/24 hr (A) and ethanol-preference ratio (B) by
Mc3r−/− and Mc3r+/+mice after ICV infusion of MTII (1.0 μg) or aCSF. All values are means
± SEM. ANO-VAs indicated that MTII significantly reduced ethanol drinking in both
Mc3r−/− and Mc3r+/+ mice.
*p < 0.05 relative to aCSF infusion.
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Consumption of 20% ethanol (B) and food intake (B) expressed as g/kg/2 hr by C57BL/6J
mice after ICV infusion of MC4R agonist (1.0 or 3.0 μg) or aCSF. All values are means ±
SEM. ANOVAs indicated that the MC4R agonist significantly reduced ethanol drinking and
food intake by mice.
*p < 0.05 relative to aCSF infusion.
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Consumption of 20% ethanol (A) and food intake (B) expressed as g/kg/8 hr by C57BL/6J
mice after ICV infusion of the MCR antagonist AgRP-(83-132) (0.05 or 0.1 μg) or aCSF.
Plasma ethanol levels 2 and 4 hr after ip injection of 4.0 g ethanol/kg (C). Ten minutes before
ethanol injection, mice were given ICV infusion of AgRP-(83-132) (0.05 μg) or aCSF. All
values are means ± SEM. ANOVAs indicated that the 0.05-μg dose of AgRP-(83-132)
significantly increased ethanol drinking but did not alter food intake. Furthermore, pretreatment
with AgRP-(83-132) did not influence plasma ethanol levels
*p < 0.05 relative to aCSF infusion.
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